Bronnen:
- Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77:1295-1302.
Bronnen:
nov 2022 | Psoriasis
nov 2020
okt 2020
aug 2020 | RA, SLE